

Contains Nonbinding Recommendations

Draft - Not for Implementation

Draft Guidance on Ponesimod

October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient:	Ponesimod
Dosage Form:	Tablet
Route:	Oral
Strengths:	2 mg, 3 mg, 4 mg, 5 mg, 6 mg 7 mg, 8 mg, 9 mg, 10 mg, 20 mg
Recommended Study:	One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 2 mg
Subjects: Healthy males and non-pregnant, non-lactating females
Additional comments: Exclude subjects with abnormal complete blood count or liver function tests. Exclude subjects with electrocardiogram abnormalities (e.g., bradycardia [or heart rate <50 beat per minute] or atrioventricular conduction abnormalities). Monitor for four hours after dosing for signs and symptoms of bradycardia with hourly pulse and blood pressure measurements. Female subjects of reproductive potential should use non-hormonal contraception during the study and continue to use effective contraception for two weeks after the last dose. Subjects should be informed not to use live attenuated vaccines at least 1 month prior, during, and for up to 2 weeks after the study. Ensure an adequate washout period between treatments in the crossover study due to the long elimination half-life of ponesimod. Alternatively, a parallel study design may be considered.

Analyte to measure: Ponesimod in plasma

Bioequivalence based on (90% CI): Ponesimod

Waiver request of in vivo testing: 3 mg, 4 mg, 5 mg, 6 mg 7 mg, 8 mg, 9 mg, 10 mg and 20 mg strengths based on (i) acceptable bioequivalence study on the 2 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units for each of all strengths of the test product and reference listed drug (RLD).¹ Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended November 2022; Revised October 2024

Unique Agency Identifier: PSG_213498

¹ If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.